News

The FDA has approved an sBLA for deflazacort that expands the label to patients aged 2 to 5 with Duchenne muscular dystrophy.

The highly specific myostatin activation inhibitor is expected to enter phase 2 study in spinal muscular atrophy, according to SRK-015’s manufacturer, Scholar Rock.

The FDA has set a PDUFA date of March 25, 2020.

The director of Behavioral Medicine at the Mellen Center for MS Treatment and Research at the Cleveland Clinic spoke about the importance of caring for patients with MS by using a team-based approach.

Zilucoplan, also being developed for generalized myasthenia gravis, is expected to enter into a phase 2 clinical trial in IMNM in the second half of 2019, according to Ra Pharma.

Are his symptoms related to a fall that occurred 2 years earlier at work?

New case-control findings suggest that glutamate and glutamine content may play a crucial role in the pathophysiology of functional motor symptoms.

The soft, garment-like device assists with forward propulsion and ground clearance in patients with gait impairments accumulated after experiencing a stroke.

The program director of neurology at Zucker School of Medicine, Northwell Health, reviewed the contributions of neurologist S. Weir Mitchell, MD, and how today’s neurologists can gain insights for their own practice from Mitchell’s complicated history.

The assistant clinical investigator, Neuro Vascular Brain Imaging Unit, NINDS, further elaborated on the findings of a retrospective analysis that reported that approximately half of stroke patients who present outside of thrombolysis treatment time windows without large vessel occlusion may benefit from reperfusion therapy.